All the news

Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ...

Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ...

Losing weight may be especially difficult for people with fatty liver disease due to differences in their metabolism. But nonetheless, some can succeed and doing so improves liver health, according to studies ...

A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ...

Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ...